Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$123.05 USD

123.05
5,931,223

-0.97 (-0.78%)

Updated May 3, 2024 04:00 PM ET

After-Market: $123.01 -0.04 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (196 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study

Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.

Viking (VKTX) Stock Down on Novo Nordisk's Obesity Pill Data

Viking Therapeutics (VKTX) falls as VK2735's placebo-adjusted mean weight loss after 13 weeks of treatment in a phase II study appears similar to Novo Nordisk's amycretin in a phase I study.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Davita (DVA) Shares Gain This Week: Will the Rally Continue?

DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.

Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success

Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.

New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Derek Lewis headshot

Stock Splits: Should You Buy?

A retail giant has recently undergone a split, hoping to make shares more accessible. But is buying post-split a viable strategy?

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Carrols, Nextracker, Costco in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Why This 1 Medical Stock Could Be a Great Addition to Your Portfolio

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense

Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.

Why Novo Nordisk (NVO) is a Top Stock for the Long-Term

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Costco, GigaCloud, Novo Nordisk in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Bryan Hayes headshot

Is It Really Just the Magnificent 7 Propping Up This Market?

The choir has been preaching that these seven stocks are holding up an overall weak market.

Kinjel Shah headshot

Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals

Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.

Amgen (AMGN) Q4 Earnings Top, Horizon Drugs Drive Sales

Amgen (AMGN) beats fourth-quarter estimates for earnings and sales. Horizon's products add $954 million in sales in the quarter.

Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings

Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.

Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales

Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.

Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B

Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.

Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?

Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year.

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, AbbVie and Novartis

Eli Lilly, Novo Nordisk, AbbVie and Novartis have been highlighted in this Industry Outlook article.

3 Reasons Growth Investors Will Love Novo Nordisk (NVO)

Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.

Bristol-Myers (BMY) Q4 Earnings & Sales Beat, Stock Gains

Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.